Orris

Oral hypoglycemic drugs

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I got a lot of content from the Katzung chapter in the earlier large read (offset 3847, 300 lines) which was truncated. I have comprehensive data from the sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors sections in the truncated output. Let me now compile a comprehensive answer from all the content collected. I have enough information from the Katzung pharmacology textbook to provide a thorough, well-organized response.

Oral Hypoglycemic Drugs (Antidiabetic Agents)

Based on Katzung's Basic and Clinical Pharmacology, 16th Edition and Goldman-Cecil Medicine.

Overview

Oral hypoglycemic drugs (also called oral glucose-lowering agents) are used primarily in type 2 diabetes mellitus, where tissue insulin resistance and relative insulin deficiency coexist. They work through several distinct mechanisms: stimulating insulin secretion, improving insulin sensitivity, slowing carbohydrate absorption, or increasing renal glucose excretion.

Classification

1. Insulin Secretagogues

A. Sulfonylureas

Mechanism: Bind to the 140-kDa sulfonylurea receptor (SUR1) on pancreatic beta cells, which is associated with an ATP-sensitive K+ channel (K_ATP). Binding inhibits K+ efflux → membrane depolarization → voltage-gated Ca²+ channel opens → Ca²+ influx → release of preformed insulin.
Generations:
GenerationDrugs
1stTolbutamide, chlorpropamide, tolazamide, acetohexamide
2ndGlibenclamide (glyburide), glipizide, glimepiride
Key pharmacology:
  • Metabolized by the liver; metabolites are excreted renally (and partly in bile for 2nd-generation)
  • 2nd-generation drugs have much greater receptor affinity at lower doses → fewer drug interactions
  • Acetohexamide is unique: its metabolite is more active than the parent compound
  • Chlorpropamide has the longest half-life (~35 hours) and can cause SIADH (dilutional hyponatremia)
Adverse effects:
  • Hypoglycemia (most important; especially with chlorpropamide, glyburide)
  • Weight gain
  • Rare: skin rashes, hematologic toxicity (leukopenia, thrombocytopenia) in <0.1%
  • Disulfiram-like reaction with alcohol (especially chlorpropamide)
  • Drug interactions: sulfonamides, salicylates, clofibrate displace from plasma proteins → potentiate hypoglycemia
UKPDS: Found no excess cardiovascular mortality with sulfonylureas (unlike the flawed 1970 UGDP study).

B. Meglitinides (Non-Sulfonylurea Secretagogues)

Drugs: Repaglinide, nateglinide
Mechanism: Also bind to the sulfonylurea receptor (same K_ATP channel), but at a different binding site. They are rapid-acting and short-duration insulin releasers - taken with each meal to cover postprandial glucose spikes.
Key features:
  • Repaglinide: metabolized by liver (CYP3A4); safe in renal impairment
  • Nateglinide: phenylalanine derivative; even faster onset; less risk of hypoglycemia
  • Main advantage: flexibility - if a meal is skipped, the dose is omitted
Adverse effects: Hypoglycemia (less than sulfonylureas), weight gain

2. Insulin Sensitizers

A. Biguanides - Metformin

The most widely prescribed oral antidiabetic drug.
Mechanism:
  • Activates AMP-activated protein kinase (AMPK) via inhibition of complex I of the mitochondrial respiratory chain
  • Primary action: Reduces hepatic glucose output (suppresses gluconeogenesis and glycogenolysis)
  • Also improves peripheral glucose uptake in muscle
  • Does NOT cause hypoglycemia when used alone (no effect on insulin secretion)
  • Does NOT cause weight gain (weight-neutral to mild weight loss)
UKPDS benefit: Metformin reduced macrovascular events and mortality in overweight type 2 diabetic patients - a landmark finding.
Pharmacokinetics:
  • Not metabolized; excreted unchanged by kidneys
  • Plasma half-life ~2 hours; eliminated within 12 hours in normal renal function
Adverse effects:
  • GI effects: nausea, diarrhea, anorexia (most common - take with food to reduce)
  • Lactic acidosis: rare but potentially fatal; risk increases with renal impairment, hepatic failure, alcohol use, contrast media, or hypoxic states - contraindicated when eGFR <30 mL/min/1.73m²
  • Vitamin B12 malabsorption with long-term use
  • Metallic taste
Contraindications: Renal impairment (eGFR <30), hepatic failure, heart failure (unstable), alcoholism, contrast procedures (hold 48h before)

B. Thiazolidinediones (TZDs / "Glitazones")

Drugs: Pioglitazone, rosiglitazone (restricted use)
Mechanism: Bind to peroxisome proliferator-activated receptor gamma (PPAR-γ) in adipose, liver, and muscle → transcriptional regulation → enhanced insulin sensitivity at peripheral tissues and liver. Reduce free fatty acid levels, improve adipokine profile (↑ adiponectin, ↓ TNF-α).
Key features:
  • Full effect takes 6-12 weeks
  • Do NOT cause hypoglycemia alone
  • Pioglitazone improves lipid profile (↑ HDL, ↓ triglycerides); rosiglitazone raises LDL
Adverse effects:
  • Fluid retention / edema - major concern; can precipitate or worsen heart failure
  • Weight gain (fat redistribution - increases subcutaneous fat)
  • Bone loss / fractures (especially distal limb fractures in women)
  • Rosiglitazone: associated with increased MI risk → restricted/withdrawn in many countries
  • Pioglitazone: possible increased bladder cancer risk with long-term use
Contraindications: Heart failure (NYHA Class III-IV), active bladder cancer (pioglitazone), hepatic disease

3. Alpha-Glucosidase Inhibitors

Drugs: Acarbose, miglitol, voglibose
Mechanism: Competitively inhibit intestinal alpha-glucosidases (maltase, sucrase, glucoamylase) and pancreatic alpha-amylase → delays digestion and absorption of complex carbohydrates and disaccharides → blunts postprandial hyperglycemia.
Key features:
  • Act locally in the gut; minimal systemic absorption (acarbose); miglitol is absorbed
  • No hypoglycemia when used alone
  • Modest HbA1c reduction (~0.5-0.8%)
  • Must be taken with the first bite of each meal
Adverse effects:
  • Flatulence, bloating, diarrhea, abdominal cramps (very common; due to undigested CHO fermentation in colon)
  • Rarely: elevated liver transaminases (acarbose at high doses)
  • If hypoglycemia occurs while on these drugs (combined therapy), treat with glucose (dextrose), NOT sucrose - because sucrase is inhibited
Contraindications: Inflammatory bowel disease, intestinal obstruction, renal impairment (miglitol if eGFR <25)

4. DPP-4 Inhibitors ("Gliptins")

Drugs: Sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin
Mechanism: Inhibit dipeptidyl peptidase-4 (DPP-4), the enzyme that degrades endogenous GLP-1 and GIP (incretin hormones) → ↑ incretin levels → glucose-dependent stimulation of insulin secretion + suppression of glucagon. Effects are glucose-dependent (only work when glucose is elevated).
Key features:
  • Weight neutral
  • Low hypoglycemia risk
  • Oral, once-daily dosing
  • Linagliptin is unique: excreted unchanged in bile; safe in renal impairment without dose adjustment
Adverse effects:
  • Nasopharyngitis, upper respiratory infections (class effect)
  • Rare: acute pancreatitis
  • Saxagliptin: associated with increased heart failure hospitalizations (FDA warning)
  • Rare: severe joint pain (arthralgia)

5. GLP-1 Receptor Agonists (Injectable - for completeness)

Drugs: Liraglutide, semaglutide (oral form available), exenatide, dulaglutide, albiglutide
Mechanism: Mimic GLP-1 → glucose-dependent insulin release, suppress glucagon, slow gastric emptying, promote satiety.
Key benefits:
  • Significant weight loss
  • Cardiovascular benefit: liraglutide and semaglutide reduce MACE (MI, stroke, CV death) - LEADER and SUSTAIN-6 trials
  • Semaglutide has an oral formulation (Rybelsus)
Adverse effects: Nausea, vomiting, pancreatitis, thyroid C-cell tumors (animal data - avoid in MEN2/medullary thyroid cancer)

6. SGLT-2 Inhibitors ("Gliflozins")

Drugs: Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin
Mechanism: Inhibit sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubule → block ~90% of glucose reabsorption → glucosuria (excrete ~60-80 g glucose/day in urine).
Key benefits (beyond glucose lowering):
  • Heart failure: Empagliflozin (EMPA-REG OUTCOME) and dapagliflozin (DAPA-HF) reduce mortality and HF hospitalizations - approved for HFrEF with or without diabetes
  • Renal protection: Slow progression of diabetic nephropathy
  • Weight loss (caloric loss via glucosuria)
  • Modest blood pressure reduction
  • Canagliflozin: reduces renal events in diabetic nephropathy (CREDENCE trial)
Adverse effects:
  • Genital mycotic infections (most common - due to glucosuria) - more in women
  • Urinary tract infections
  • Euglycemic diabetic ketoacidosis (rare but serious - can occur in type 1 or perioperatively)
  • Canagliflozin: increased lower limb amputations, bone fractures
  • Volume depletion / hypotension
  • Fournier's gangrene (necrotizing fasciitis of genitalia - rare)
Contraindicated in: eGFR <30 (glucose-lowering effect lost), recurrent UTI/genital infections

7. Other / Miscellaneous

DrugClassMechanismNotes
PramlintideAmylin analogSlows gastric emptying, suppresses glucagon, promotes satietyInjectable; used with insulin
ColesevelamBile acid sequestrantMechanism unclearModest HbA1c reduction; also lowers LDL
BromocriptineDopamine agonistResets hypothalamic circadian clock; improves insulin sensitivityTake within 2h of waking

Comparison Summary Table

Drug ClassMechanismHypoglycemia RiskWeight EffectKey Advantage
Sulfonylureas↑ Insulin secretion (K_ATP block)YesGainCheap, effective
Meglitinides↑ Insulin secretion (prandial)LowGainFlexible dosing
Metformin↓ Hepatic glucose output (AMPK)NoNeutral/loss1st line; CV benefit
TZDsPPAR-γ agonist (↑ sensitivity)NoGainDurable effect
Alpha-glucosidase inhibitorsDelay CHO absorptionNoNeutralPostprandial control
DPP-4 inhibitors↑ Incretin levelsNoNeutralWell tolerated
GLP-1 agonistsGLP-1R stimulationNoLossCV + weight benefit
SGLT-2 inhibitorsGlucosuriaNoLossHF + renal protection

First-Line and Combination Therapy

  • Metformin remains the cornerstone first-line agent (unless contraindicated)
  • GLP-1 agonists or SGLT-2 inhibitors are added when cardiovascular disease, heart failure, or chronic kidney disease is present (regardless of glycemic control)
  • Sulfonylureas are still widely used as second-line add-on therapy where cost matters
  • Insulin is added when oral agents are insufficient or in late-stage disease
Source: Katzung's Basic and Clinical Pharmacology, 16th Edition, Chapter 41; Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.